[
 {
  "nct": "NCT00845507",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG000"
    ],
    "placebo_groups": [
     "EG001"
    ],
    "molecules": [
     "exenatide"
    ],
    "background": "olanzapine"
   }
  ],
  "population": "other",
  "population_note": "Obese adults with olanzapine-associated weight gain and bipolar disorder, major depressive disorder, schizophrenia or schizoaffective disorder; diabetes status not stated.",
  "note": "",
  "reason": "Both codings agree on the comparison. Under Population, a group defined by a condition beyond overweight or obesity (here serious mental illness with olanzapine-associated weight gain) is `other`, as the codebook does for PCOS or heart failure, and diabetes isn't stated to be excluded, so `overweight_obesity` ('without diabetes') isn't established."
 },
 {
  "nct": "NCT01514149",
  "eligible": false,
  "exclusion_reason": "no_glp1_group",
  "comparisons": [],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "CJC-1134-PC is named only by code; it is not on the codebook list and the record never describes it as a GLP-1 receptor agonist. Were it so described, EG000-EG003 vs EG004 on metformin would be a clean comparison.",
  "reason": "A GLP-1 group needs a listed molecule or 'another molecule the record describes as a GLP-1 receptor agonist'; the record says nothing about what CJC-1134-PC is, and being found by the intervention search doesn't establish its class."
 },
 {
  "nct": "NCT01590433",
  "eligible": false,
  "exclusion_reason": "background_differs",
  "comparisons": [],
  "population": "overweight_obesity",
  "population_note": "Overweight and obese women without diabetes.",
  "note": "Only the placebo arm lists dietary counseling as an intervention, its group says participants 'may or may not be asked to follow a reduced calorie diet', and the truncated arm texts diverge ('exenatide will not be as[ked]...' vs 'placebo will be assigned...'): placebo participants appear to have been assigned a reduced-calorie diet the exenatide group wasn't. If the diets were in fact identical, EG000 vs EG001 would be clean.",
  "reason": "A placebo group must have 'the same co-interventions' as the GLP-1 group; the record indicates a diet assigned to the placebo arm only, so the groups differ in more than exenatide."
 },
 {
  "nct": "NCT01667900",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG005",
     "EG006",
     "EG007"
    ],
    "placebo_groups": [
     "EG004"
    ],
    "molecules": [
     "dulaglutide"
    ],
    "background": "none stated"
   }
  ],
  "population": "mixed",
  "population_note": "Part A healthy Chinese volunteers, Part B Chinese patients with type 2 diabetes; the comparison is Part B (type 2 diabetes) only.",
  "note": "Part A groups (EG000-EG003) are single doses given 'in 1 of 3 treatment periods', so each participant had several treatments and the groups overlap; left out. Part B is parallel, weekly for 4 weeks.",
  "reason": "Part A is a crossover whose groups are treatment periods rather than randomized arms, which the codebook leaves out ('isn't a randomized arm over the randomized period'); Part B's parallel dose groups against its placebo are the only clean comparison."
 },
 {
  "nct": "NCT01870297",
  "eligible": false,
  "exclusion_reason": "no_placebo_group",
  "comparisons": [],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "LY3025876 is not described as a GLP-1 receptor agonist, so Part A has no GLP-1 group. In Part B, EG006 got the LY3025876 placebo plus liraglutide as a separate injection after a 2-week titration, and EG005 got the same LY3025876 placebo with no liraglutide dummy: the placebo is background shared by both, liraglutide was unmasked, and its group had 2 extra weeks of treatment.",
  "reason": "A placebo group must get a placebo for the GLP-1 drug, or one standing in for it in a double-blind design; EG005's only placebo is one the liraglutide group also got, so for liraglutide it is a no-treatment control with no placebo, which 'What doesn't count' leaves out."
 },
 {
  "nct": "NCT02020616",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG006"
    ],
    "placebo_groups": [
     "EG000"
    ],
    "molecules": [
     "exenatide"
    ],
    "background": "metformin"
   }
  ],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "LY3053102 is not described as a GLP-1 receptor agonist, so its groups (EG001-EG005) are left out. Exenatide ER (labelled active comparator) vs the LY3053102-matched placebo, both weekly SC on metformin for 12 weeks, triple-masked; the exenatide arm lists no LY3053102 placebo, so the placebo stands in for active treatment. No LY3053102 + exenatide group was reported.",
  "reason": "The codebook's placebo group includes 'no added drug in a double-blind design, e.g. a placebo injection', not only a placebo matched to the GLP-1 drug; EG000 got only a placebo injection with the same metformin and period, so EG006 vs EG000 differs only in exenatide."
 },
 {
  "nct": "NCT02664441",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG000"
    ],
    "placebo_groups": [
     "EG001"
    ],
    "molecules": [
     "exenatide"
    ],
    "background": "none"
   }
  ],
  "population": "other",
  "population_note": "Hypothalamic obesity after craniopharyngioma or other hypothalamic tumours; diabetes status not stated.",
  "note": "36-week double-blind groups only; EG002 is the 18-week open-label exenatide extension, left out.",
  "reason": "Both codings agree on the comparison. Under Population, obesity defined by another condition (hypothalamic damage from tumours) goes to `other`, as the codebook does for PCOS or heart failure, and diabetes isn't stated to be excluded."
 },
 {
  "nct": "NCT02973321",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG005"
    ],
    "placebo_groups": [
     "EG000"
    ],
    "molecules": [
     "liraglutide"
    ],
    "background": "metformin"
   }
  ],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "SAR425899 is not on the list and the record doesn't describe it as a GLP-1 receptor agonist, so EG001-EG004 (which are also grouped by dose received at week 8) are left out. Liraglutide (labelled active comparator) vs the SAR425899 placebo, both daily SC on metformin for 26 weeks, quadruple-masked; the liraglutide arm lists no SAR425899 placebo.",
  "reason": "The codebook's placebo group includes 'no added drug in a double-blind design, e.g. a placebo injection' even when the placebo was made for another drug; EG000 has the same metformin and 26 weeks as EG005, so liraglutide vs placebo is clean."
 },
 {
  "nct": "NCT04311411",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG001",
     "EG002"
    ],
    "placebo_groups": [
     "EG000"
    ],
    "molecules": [
     "tirzepatide",
     "liraglutide"
    ],
    "background": "none"
   }
  ],
  "population": "overweight_obesity",
  "population_note": "",
  "note": "Liraglutide (labelled active comparator; daily SC escalating to 3 mg, about 5.5 weeks of dosing) pooled with tirzepatide against the SC placebo of this double-blind trial; the record doesn't say liraglutide was open-label or what the placebo matched. AE groups are by regimen received.",
  "reason": "Any group randomized to a listed GLP-1 drug is a GLP-1 group whatever its arm label, and a placebo injection with no added drug in a double-blind design is a placebo group; since a group joins at most one comparison, both GLP-1 groups are pooled against EG000."
 },
 {
  "nct": "NCT04741074",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG000"
    ],
    "placebo_groups": [
     "EG001"
    ],
    "molecules": [
     "semaglutide"
    ],
    "background": "none"
   }
  ],
  "population": "mixed",
  "population_note": "Obesity with stage 4-5 CKD or dialysis-dependent ESKD, with or without type 2 diabetes (diabetic kidney disease and type 2 diabetes listed alongside obesity and CKD).",
  "note": "Semaglutide arm labelled active comparator; placebo matched, with the same escalation instructions.",
  "reason": "The conditions list obesity and CKD alongside type 2 diabetes and diabetic kidney disease, so diabetes is allowed but not required; Population's `mixed` is for a population that mixes people with and without diabetes by design."
 },
 {
  "nct": "NCT04867785",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG001",
     "EG002",
     "EG003",
     "EG004",
     "EG005",
     "EG006",
     "EG007"
    ],
    "placebo_groups": [
     "EG000"
    ],
    "molecules": [
     "retatrutide",
     "dulaglutide"
    ],
    "background": "none"
   }
  ],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "LY3437943 is retatrutide. Dulaglutide (labelled active comparator) included: weekly SC like the placebo in a double-blind trial, and the record doesn't describe it as open-label or the placebo as matching LY3437943 only.",
  "reason": "Any group randomized to a listed GLP-1 drug is a GLP-1 group whatever its arm label, and a placebo injection with no added drug in a double-blind design is a placebo group; nothing in the record says the dulaglutide arm was unmasked, so it joins the one comparison against EG000."
 },
 {
  "nct": "NCT05048719",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG001",
     "EG002",
     "EG003",
     "EG004",
     "EG005",
     "EG006",
     "EG007",
     "EG008"
    ],
    "placebo_groups": [
     "EG000"
    ],
    "molecules": [
     "orforglipron",
     "dulaglutide"
    ],
    "background": "none"
   }
  ],
  "population": "type2_diabetes",
  "population_note": "",
  "note": "LY3502970 is orforglipron. Dulaglutide (labelled active comparator; SC weekly, while LY3502970 is oral daily) included against the 'matching placebo' of this double-blind trial; the record doesn't say what the placebo matched or that dulaglutide was open-label.",
  "reason": "Any group randomized to a listed GLP-1 drug is a GLP-1 group whatever its arm label, and placebo with no added drug in a double-blind design is a placebo group; the record gives no sign the dulaglutide arm was unmasked, so it joins the one comparison against EG000."
 },
 {
  "nct": "NCT05364931",
  "eligible": true,
  "exclusion_reason": null,
  "comparisons": [
   {
    "glp1_groups": [
     "EG000",
     "EG001"
    ],
    "placebo_groups": [
     "EG002",
     "EG003"
    ],
    "molecules": [
     "cotadutide"
    ],
    "background": "none"
   }
  ],
  "population": "other",
  "population_note": "Non-cirrhotic NASH with fibrosis.",
  "note": "Each cotadutide dose has a volume-matched placebo group; placebo volume is not a different background, so doses and placebos are pooled. Group descriptions are placeholders; identities from titles.",
  "reason": "The codebook allows several comparisons only for a factorial design or separate background regimens, and lets doses be pooled; two placebo volumes are not two backgrounds, so this is one comparison."
 },
 {
  "nct": "NCT06771115",
  "eligible": false,
  "exclusion_reason": "no_placebo_group",
  "comparisons": [],
  "population": "overweight_obesity",
  "population_note": "",
  "note": "Factorial with VTX3232: semaglutide was injected on top of oral VTX3232 or its oral placebo, and the groups without semaglutide got no placebo injection, so the oral placebo is background shared by both sides and semaglutide was unmasked. If accepted, EG002 vs EG000 and EG003 vs EG001.",
  "reason": "A placebo group must get a placebo for the GLP-1 drug, or one standing in for it in a double-blind design; EG000 and EG001 got the same oral treatment as their semaglutide counterparts and no injection, so they are open-label no-treatment controls for semaglutide, which 'What doesn't count' leaves out."
 }
]